Holen Sie sich die Stockscreener-App
3.08
6.95%
-0.23
Handel nachbörslich:
3.06
-0.02
-0.65%
Schlusskurs vom Vortag:
$3.31
Offen:
$3.4
24-Stunden-Volumen:
97,289
Relative Volume:
0.65
Marktkapitalisierung:
$13.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-0.9477
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
-11.24%
1M Leistung:
-21.43%
6M Leistung:
-36.49%
1J Leistung:
+890.35%
1-Tages-Spanne:
$3.06
$3.40
1-Wochen-Bereich:
$3.06
$3.72
52-Wochen-Spanne:
$0.2298
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Vergleichen Sie CLRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.08 | 14.03M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Cellectar Advances CLR 125 Into Early Breast Cancer Trial, Adding Depth to Its Radiotherapy Pipeline - TipRanks
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - Investing News Network
Cellectar Biosciences to highlight strategic initiatives for 2026 - MarketScreener
Cellectar Biosciences Outlines 2026 Strategic Plan and Regulatory Milestones for Iopofosine I 131 and CLR 125 at Biotech Showcase - Quiver Quantitative
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase ... - Bluefield Daily Telegraph
Cancer-focused biotech maps 2026 push in blood and breast tumors - Stock Titan
HOKA Comfort Guide: Is Cellectar Biosciences Inc. stock dividend yield sustainableWide Width Options & support options for steady strides - ulpravda.ru
How Cellectar Biosciences Inc. stock performs in rate cut cyclesWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Sentiment Review: What catalysts could drive Cellectar Biosciences Inc stock higherPortfolio Profit Report & Low Risk Entry Point Guides - moha.gov.vn
ABTBiotech Stocks Forge Ahead With Confidence on This Week's Healthy Biotech Rally - ADVFN
What catalysts could drive Cellectar Biosciences Inc. stock higherJuly 2025 Catalysts & Weekly Breakout Watchlists - ulpravda.ru
Why retail investors favor Cellectar Biosciences Inc. stockStop Loss & Real-Time Buy Signal Notifications - ulpravda.ru
Momentum Shift: Will Cellectar Biosciences Inc. stock outperform value stocksMarket Performance Recap & Weekly High Conviction Trade Ideas - ulpravda.ru
Published on: 2026-01-09 06:04:32 - ulpravda.ru
Is Cellectar Biosciences Inc. stock ready for breakoutForecast Cut & High Yield Stock Recommendations - ulpravda.ru
Trend Report: What catalysts could drive Cellectar Biosciences Inc. stock higherWeekly Market Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Bond Watch: Why retail investors favor Cellectar Biosciences Inc. stock2025 Volume Leaders & Weekly Momentum Stock Picks - ulpravda.ru
Is Cellectar Biosciences Inc. stock a buy before product launchesWeekly Loss Report & AI Forecast Swing Trade Picks - ulpravda.ru
Is Cellectar Biosciences Inc. stock attractive for retirement portfoliosJuly 2025 Sentiment & Proven Capital Preservation Methods - ulpravda.ru
Will Cellectar Biosciences Inc. stock beat EPS estimatesJuly 2025 Sector Moves & Community Verified Watchlist Alerts - ulpravda.ru
Why Cellectar Biosciences Inc. stock could rally in 2025Earnings Per Share Trends & Affordable Market Strategies - ulpravda.ru
Trade Report: Why Rezolve AI PLC stock appeals to dividend seekersWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
What drives Cellectar Biosciences Inc stock priceHealthcare Stock Analysis & Affordable Growth Trading - earlytimes.in
Targets Report: Why retail investors favor Cellectar Biosciences Inc stockMarket Growth Review & Accurate Entry/Exit Alerts - moha.gov.vn
Layoff Watch: Will Cellectar Biosciences Inc stock outperform value stocksBond Market & Community Verified Trade Signals - moha.gov.vn
Can Ahimsa Industries Limited Regain Momentum After BreakdownMarket Rumors and News & Affordable Stock Market Tips - earlytimes.in
Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Investor Takeaways & Real-Time Volume Spike Alerts - Улправда
How Cellectar Biosciences Inc. (NV4) stock reacts to weak economyJuly 2025 WrapUp & Smart Allocation Stock Reports - Bölüm Sonu Canavarı
Will Cellectar Biosciences Inc. stock benefit from sector rotation2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
Why Cellectar Biosciences Inc. stock remains undervaluedJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Aug Swings: Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Historical Comparison & Weekly Watchlist of Top Performers - ulpravda.ru
How Cellectar Biosciences Inc. stock trades before earningsJuly 2025 Volume & Low Risk Entry Point Tips - Улправда
Should I buy Cellectar Biosciences Inc. (NV4) stock before earnings seasonJuly 2025 Update & Real-Time Market Trend Scan - DonanımHaber
What MACD trends signal for Cellectar Biosciences Inc. (NV4) stock2025 Short Interest & Verified Momentum Stock Alerts - Улправда
Bond Watch: Why Cellectar Biosciences Inc. stock could rally in 2025July 2025 Setups & Momentum Based Trading Ideas - Улправда
Cellectar Biosciences announces supply agreement with Ionetix - MSN
Cellectar Biosciences, Inc. (CLRB) director John Neis reports stock sale - Stock Titan
Cellectar secures multi-year supply of alpha-emitting radioisotopes By Investing.com - Investing.com Australia
Cellectar Biosciences : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Cellectar Biosciences announces strategic supply agreement with Ionetix - marketscreener.com
Cellectar Biosciences (CLRB) Secures Supply Agreement for Radioi - GuruFocus
Cellectar secures multi-year supply of alpha-emitting radioisotopes - Investing.com
Cellectar Biosciences Announces Multi-Year Supply Agreement with Ionetix for Alpha-Emitting Radioisotopes - Quiver Quantitative
Cellectar Biosciences IncAnnounces Multi-Y - 富途牛牛
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies - GlobeNewswire
Cellectar Biosciences Earnings Notes - Trefis
MACD Signal: How Cellectar Biosciences Inc NV4 stock performs in easing cyclesRate Hike & Smart Money Movement Tracker - moha.gov.vn
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight - The Globe and Mail
Cellectar Biosciences (CLRB) price target decreased by 44.05% to 47.94 - MSN
Can Cellectar Biosciences Inc. (NV4) stock retain market dominance2025 Top Decliners & Proven Capital Preservation Methods - Newser
Will Cellectar Biosciences Inc. (NV4) stock deliver compounding returnsWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cellectar Biosciences Inc-Aktie (CLRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
11,638 |
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):